



Europäisches Patentamt
European Patent Office
Office européen des brevets

⑪ Publication number:

0 046 409
A1

⑫

EUROPEAN PATENT APPLICATION

⑬ Application number: 81303770.2

⑮ Int. Cl.: **A 61 K 31/375, C 07 F 1/08,**
C 07 C 51/41, C 07 C 59/105,
A 01 N 43/08

⑭ Date of filing: 19.08.81

⑯ Priority: 20.08.80 AU 5138/80

⑰ Applicant: Waliczek, Erwin Günther, 13 Blarritz Avenue,
Beaumaris Victoria 3193 (AU)

⑲ Date of publication of application: 24.02.82
Bulletin 82/8

⑳ Inventor: Waliczek, Erwin Günther, 13 Blarritz Avenue,
Beaumaris Victoria 3193 (AU)

㉑ Designated Contracting States: AT BE CH DE FR GB IT
LI LU NL SE

㉒ Representative: Holdcroft, James Gerald et al, Graham
Watt & Co. Riverhead, Sevenoaks Kent TN13 2BN (GB)

㉓ A process for the preparation of a solution of a cuprous complex; solutions of the cuprous complexes for use in the therapeutic treatment of the human or animal body; and a method of therapeutic treatment of a plant.

㉔ A solution of a cuprous complex is prepared by a process in which a cupric halide is dissolved in a solvent consisting of one or more of ethyl alcohol or a liquid primary alcohol containing 3 or more carbon atoms, polypropylene glycol, propylene glycol, polyethylene glycol, ethylene glycol or other liquid glycol, glycerol or other liquid triol, an aliphatic betaine and a sulphobetaine, the concentration of Cu being not less than 0.01% w/v; ascorbic acid not less than 90% of the weight of the Cu present or the equivalent weight of a non-toxic ascorbate, is added and dissolved under an inert atmosphere; and the pH of this solution, if less than 4, is adjusted to 4 to 6 by the addition of an alkali.

The solutions of the cuprous complexes are useful in the topical therapeutic treatment of the human or animal body suffering from any of fungal, inflammatory or viral complaints, arthritis, rheumatism, warts, herpes or carcinoma; papilloma; and also in the topical treatment of plants affected with fungal disorders.

A1


409

0 046

A PROCESS FOR THE PREPARATION OF A SOLUTION OF
A CUPROUS COMPLEX; SOLUTIONS OF THE CUPROUS
COMPLEXES FOR USE IN THE THERAPEUTIC TREATMENT
OF THE HUMAN OR ANIMAL BODY; AND A METHOD OF
THERAPEUTIC TREATMENT OF A PLANT

This invention relates to the preparation of a solution of a cuprous complex and it refers more particularly to one wherein a cupric halide is dissolved
10 in a solvent consisting of one or more of ethyl alcohol or a liquid primary alcohol containing 3 or more carbon atoms, polypropylene glycol, propylene glycol, polyethylene glycol, ethylene glycol or other liquid glycol, glycerol or other liquid triol, an aliphatic betaine e.g. having a
15 pH between 3.5 and 6.0, and a sulpho-betaine e.g. having a pH between 3.5 and 6.0, the concentration of Cu being not less than 0.01% w/v of said solution; ascorbic acid not less than 90% of the weight of the Cu present or the equivalent weight of a non-toxic ascorbate, is added and
20 dissolved under an inert atmosphere; and the pH of this solution, if less than 4, is adjusted to 4 to 6 by the addition of an alkali.


The aliphatic betaines used in embodiments of this invention conform to formula



wherein R is an aliphatic radical containing not more
5 than 18 carbon atoms, and optionally containing an amide
linkage; R₁ and R₂, which may be the same or different,
are alkyl groups containing not more than 3 carbon atoms
and are optionally substituted by hydroxyl.

If the pH of such a compound, as bought
10 commercially, is above 6.0, it may be adjusted to 3.5 to
6.0 by the addition of a hydrohalic acid, before use in
the above process.

The sulpho-betaines used in embodiments of this
invention conform to formula



R, R₁ and R₂ being as defined above. As in the case of
the aliphatic betaines, the pH of the commercial product,
20 if above 6.0, is adjusted to 3.5 to 6.0 by the addition of
a hydrohalic acid, before use in the above process.

The preferred cupric halide is CuCl₂.2H₂O.

The preferred solvents are propylene glycol, and
aliphatic betaines of pH between 3.5 and 6.0. Both of
25 these have documented non-toxic properties.

The preferred aliphatic betaines are those in which R is a predominantly alkyl radical having from 12 to 14 carbon atoms, and R_1 and R_2 are both methyl. These are sold commercially as Empigen BB. If the pH is above 5 6.0, it is preferably adjusted to 3.5 to 6.0 by strong hydrochloric acid. The preferred pH within the range of 3.5 to 6.0, is 4.

The preferred concentration of Cu in stock solutions which may be diluted for use with a pharmaceutically acceptable diluent, depends on the composition of 10 the solvent. When the solvent is a glycol or glycerol, the preferred concentration of Cu is 10% w/v. When the solvent is an aliphatic betaine of pH 3.5 to 6.0 or a sulpho-betaine of pH 3.5 to 6.0, the preferred concentration 15 of Cu is 5% w/v.

The preferred proportion of ascorbic acid is 100% of the weight of the Cu present. The non-toxic ascorbates include but are not restricted to the ascorbates of alkali metals, alkaline earth metals, 20 aluminium and silicon.

The preferred non-toxic ascorbate is sodium ascorbate, and its preferred proportion is 112.5% of the weight of the Cu present.

The preferred inert atmosphere is nitrogen.
25 The alkali preferred for adjusting the pH of the

solution to 4 to 6 is 10% w/v sodium hydroxide solution.

- While the cupric halide and ascorbic acid or non-toxic ascorbate can sometimes be dissolved in the solvent at ambient temperature, particularly if the
5 solvent is a glycol or triol, heating to a temperature above 60°C is more convenient and sometimes necessary. Some of the aliphatic betaine solutions of the cuprous complex set to a solid at ambient temperature, but can be re-melted at temperatures in the vicinity of 32°C.
10 The preferred temperature range for dissolving the cupric halide is 60°C to 80°C.

The cuprous complex produced by the above process is believed to be a cuprous halo ascorbate. The solutions of the cuprous complex prepared as above have
15 strong antifungal properties when applied topically on humans, animals or plants. The preferred concentration of Cu for topical application to humans or animals afflicted with ringworm or other disability caused by a fungus, is 2 to 3% w/v. The preferred concentration of Cu for
20 topical application to a plant afflicted with a disability caused by a fungus, is 0.5 to 1% w/v. It has also been found that the solution of the cuprous complex prepared by the process above is very effective in the therapeutic treatment of a human or animal suffering from rheumatism,
25 arthritis, or other inflammation; or papiloma, other warts,

herpes, carcinoma or other viral disorder.

The preferred concentration of Cu for topical application for the therapeutic treatment of a human or animal suffering from rheumatism, arthritis or other
5 inflammation, is 2 to 3% w/v.

The preferred concentration of Cu for topical application for the therapeutic treatment of a human or animal suffering from papiloma, other warts, herpes, carcinoma or other viral disorder, is 4 to 5% w/v.

10 As mentioned above, it is often convenient to prepare a stock solution having 10% w/v or 5% w/v of Cu, and diluting this for use. The preferred pharmaceutically acceptable diluent is propylene glycol.

It is also noted here that solutions of the
15 cuprous complex containing an aliphatic betaine or a sulpho-betaine, are also anti-bacterial. If, therefore, the human or animal to be treated for any of the above disabilities has an associated bacterial infection, it is preferred that the solution of the cuprous complex be one
20 that contains an aliphatic betaine or a sulpho-betaine. This could be a stock solution prepared from a primary alcohol, a glycol or a triol, but subsequently diluted with an aliphatic betaine or a sulpho-betaine.

The following non-limitative Examples illustrate
25 the invention.

EXAMPLE 1

To 1 litre of propylene glycol add 268 g CuCl₂.
2H₂O. Commence agitation and heat to about 70°C. When
the CuCl₂.2H₂O has dissolved, add 100 g ascorbic acid or
5 112.5 g sodium ascorbate. Without delay, cover the
mixture with an atmosphere of nitrogen. After the
ascorbic acid or sodium ascorbate has dissolved, propylene
glycol may be added to reduce the concentration of Cu to
a preferred value for treatment.

10 Transfer the solution, diluted or not, to
ampoules and seal. This product has no anti-bacterial
properties.

EXAMPLE 2

Check the pH of 1 litre of an aliphatic betaine
15 sold commercially as Empigen BB. If the pH is above 6.0,
add strong hydrochloric acid with agitation until the pH
is reduced to 4. With the agitation continued, add 134 g
CuCl₂.2H₂O and heat to about 70°C.

When this has dissolved, add 50 g ascorbic acid
20 or 56.25 g sodium ascorbate. Without delay, cover the
mixture with an atmosphere of nitrogen. After the ascorbic
acid or sodium ascorbate has dissolved, add 10% w/v sodium
hydroxide solution until the pH is 5.

Propylene glycol may be added to reduce the
25 concentration of Cu to a preferred value for treatment.

Transfer the solution, diluted or not, to ampoules and seal. This product has anti-bacterial properties.

ANTI-FUNGAL STUDIES

5 Field tests have shown that a concentration of 2-3% copper applied once daily will clear-up the skin disorder between 2-4 weeks. It is beneficial to apply the medication after a bath has been taken.

ANTI-INFLAMMATION STUDIES

10 Field tests have shown that a concentration of 2-3% copper applied once daily will diminish rheumatic pain and associated swellings after 3-5 days. Similar results have been obtained on haemmoroids. It is beneficial to apply the medication after a bath has been
15 taken.

ANTI-VIRAL STUDIES

Field tests have shown that a concentration of 4-5% copper applied once daily will completely remove warts, venereal warts, papiloma and dermatose fibroma
20 between 4-6 weeks.

Herpes simplex formation is arrested after a 3-4 day interval. If possible, it is beneficial to apply the medication after a bath has been taken.

CLAIMS: (Except for Austria)

1. A process for the preparation of a solution of a cuprous complex characterised in that
5 (a) a cupric halide is dissolved in a solvent consisting of one or more of ethyl alcohol or a liquid primary alcohol containing 3 or more carbon atoms, polypropylene glycol, propylene glycol, polyethylene glycol, ethylene glycol or other liquid glycol, glycerol or other liquid triol, an aliphatic betaine and a sulpho-betaine the concentration of Cu being not less than 0.01% w/v of said
10 solution; (b) ascorbic acid not less than 90% of the weight of the Cu present or the equivalent weight of a non-toxic ascorbate, is added and dissolved under an inert atmosphere; and (c) the pH of this solution, if less than
15 4, is adjusted to 4 to 6 by the addition of an alkali.

2. A process as claimed in Claim 1 wherein the cupric halide is dissolved at a temperature between 60°C and 80°C.

3. A process as claimed in Claim 1 or 2
20 wherein the cupric halide is $CuCl_2 \cdot 2H_2O$, the non-toxic ascorbate is sodium ascorbate, the weight of ascorbic acid is 100% of the weight of the Cu present or the weight of sodium ascorbate is 112.5% of the weight of the Cu present, and the inert atmosphere is nitrogen.

25 4. A process as claimed in any preceding

claim wherein the solvent is an aliphatic betaine having a pH between 3.5 and 6.0, a sulpho-betaine having a pH between 3.5 and 6.0 or a mixture of the two.

5. A process as claimed in any preceding claim, wherein the solution is additionally diluted with a pharmaceutically acceptable diluent.

6. A solution of a cuprous complex when produced by a process as claimed in any preceding claim, characterised in that the solution is for use in the 10 topical therapeutic treatment of the human or animal body suffering from any of, fungal, inflammatory or viral complaints; arthritis, rheumatism, warts, herpes or carcinoma; papiloma.

7. A solution according to claim 6, wherein 15 an aliphatic betaine or a sulpho-betaine is present, and characterised in that the solution is for use in the topical therapeutic treatment of the human or animal body also suffering from a bacterial infection associated with any of the said fungal, inflammatory or viral complaints; 20 arthritis, rheumatism, warts, herpes or carcinoma; papiloma.

8. A method of therapeutic treatment of a plant afflicted with a disability caused by a fungus, characterised by topical application of a solution 25 produced by a process as claimed in any one of Claims 1 to 5.

CLAIMS: (for Austria)

1. A process for the preparation of a solution of a cuprous complex characterised in that
 - (a) a cupric halide is dissolved in a solvent consisting of one or more of ethyl alcohol or a liquid primary alcohol containing 3 or more carbon atoms, polypropylene glycol, propylene glycol, polyethylene glycol, ethylene glycol or other liquid glycol, glycerol or other liquid triol, an aliphatic betaine and a sulpho-betaine the concentration of Cu being not less than 0.01% w/v of said solution; (b) ascorbic acid not less than 90% of the weight of the Cu present or the equivalent weight of a non-toxic ascorbate, is added and dissolved under an inert atmosphere; and (c) the pH of this solution, if less than 4, is adjusted to 4 to 6 by the addition of an alkali.
2. A process as claimed in Claim 1 wherein the cupric halide is dissolved at a temperature between 60°C and 80°C.
3. A process as claimed in Claim 1 or 2 wherein the cupric halide is CuCl₂.2H₂O, the non-toxic ascorbate is sodium ascorbate, the weight of ascorbic acid is 100% of the weight of the Cu present or the weight of sodium ascorbate is 112.5% of the weight of the Cu present, and the inert atmosphere is nitrogen.
- 25 4. A process as claimed in any preceding

claim wherein the solvent is an aliphatic betaine having a pH between 3.5 and 6.0, a sulpho-betaine having a pH between 3.5 and 6.0 or a mixture of the two.

5. A process as claimed in any preceding claim, wherein the solution is additionally diluted with a pharmaceutically acceptable diluent.

6. A method of therapeutic treatment of a plant afflicted with a disability caused by a fungus, characterised by topical application of a solution
10 produced by a process as claimed in any preceding claim.



European Patent
Office

EUROPEAN SEARCH REPORT

0046409
Application number

EP 81 30 3770

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl.)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	TECHNICAL FIELDS SEARCHED (Int. Cl.)
	<p>CHEMICAL ABSTRACTS, vol. 73, no. 19, 9th November 1970, page 25, i. 94729b Columbus, Ohio, U.S.A. A. HATANO et al.: "Behavior of copper ion with ascorbic acid" & J. VITAMINOL. (KYOTO) 1970, 16(2) 99-102 * Abstract * --</p> <p>CHEMICAL ABSTRACTS, vol. 72, no. 11, 16th March 1970, page 26, no. 51083y Columbus, Ohio, U.S.A. A. HATANO et al.: "Ascorbic acid and its complexes. V. Behavior of copper ion with ascorbic acid" & BITAMIN 1969, 40(6), 416-419 * Abstract * --</p> <p>FR - A - 2 377 393 (MARSTRAND EVEN) * Page 4, claims 1-7 * -----</p>	1-3	A 61 K 31/375 C 07 F 1/08 C 07 C 51/41 59/105 A 01 N 43/08
A		1-3	A 61 K 31/375 C 07 F 1/00
		1-8	
			CATEGORY OF CITED DOCUMENTS
			X: particularly relevant A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention E: conflicting application D: document cited in the application L: citation for other reasons
			&: member of the same patent family, corresponding document
 <p>The present search report has been drawn up for all claims</p>			
Place of search	Date of completion of the search	Examiner	
The Hague	20-11-1981	SUTER	

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.